Transistorisch-ischämische Attacke/Hirninfarkt/Sekundärprophylaxe

Alte, aber immer noch häufig eingesetzte Definition der transitorisch-ischämischen Attacke (TIA): plötzlich auftretende fokal-neurologische Ausfälle, die durch eine zerebrale Durchblutungsstörung bedingt sind und sich innerhalb von 24h komplett zurückbilden. Die neue Definition lautet: Symptomdauer der fokal-neurologischen Ausfälle <1h und im MRT kein Ischämienachweis.

• Literatur

• 1 Vahedi K, Hofmeijer J, Juettler E. et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6: 215-222
• 2 Jüttler E, Unterberg A, Woitzik J. et al. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. NEJM 2014; 370: 1091-1100
• 3 CLOTS Trials Collaboration, Dennis M, Sandercock P. et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 2013; 382: 516-524
• 4 Adams HP, Bendixen BH, Kapelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
• 5 Hankey GJ. Secondary stroke prevention. Lancet Neurol 2014; 13: 178-194
• 6 Yongjun W, Yilong W, Xingquan Z. et al. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. N Engl J Med 2013; 369: 11-19
• 7 Paciaroni M, Agnelli G, Micheli S. et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38: 423-430
• 8 Amarenco P, Davis S, Jones EF. et al. Aortic Arch Related Cerebral Hazard Trial Investigators. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014; 45: 1248-1257
• 9 Amarenco P, Kim JS, Labreuche J. et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. NEJM 2020; 382: 9-19
• 10 Mas JL, Derumeaux G, Guillon B. et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke . N Engl J Med 2017; 377: 1011-1021
• 11 Sondergaard L, Kasner SE, Rhodes JF. et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med 2017; 377: 1033-1042
• 12 Saver JL, Carroll JD, Thaler DE. et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med 2017; 377: 1022-1032
• 13 Furlan AJ, Reisman M, Massaro J. et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991-999
• 14 Meier B, Kalesan B, Mattle HP. et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083-1091
• 15 Carroll JD, Saver JL, Thaler DE. et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092-1100
• 16 Kent DM, Ruthazer R, Weimar C. et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81: 619-625
• 17 Diener H-C, Grau A, Baldus S. et al. Kryptogener Schlaganfall und offenes Foramen ovale, S2e-Leitlinie. 2018 Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Zugriff am 08. August 2022 unter: www.dgn.org/leitlinien